Posted by Michael Wonder on 02 Nov 2021
FDA grants breakthrough status for Alzheimer's treatment
2 November 2021 - Renew Bioscience announced it has received breakthrough device designation status from the U.S. FDA for the Cerezen device, a novel treatment for mild cognitive impairment due to Alzheimer's disease and mild dementia of the Alzheimer's type.
The Cerezen device utilises external counterpulsation therapy that enhances blood flow and overall vascular efficiency.
